Avalo Therapeutics (Avalo Therapeutics) Risk Assessment

View and export this data going back to 2015. Start your Free Trial

What is Avalo Therapeutics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Avalo Therapeutics is: High Risk: High uncertainty.

Competitive Comparison of Avalo Therapeutics's Risk Assessment

For the Biotechnology subindustry, Avalo Therapeutics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avalo Therapeutics's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's Risk Assessment falls into.

Avalo Therapeutics (NAS:AVTX) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Avalo Therapeutics Risk Assessment Related Terms

Thank you for viewing the detailed overview of Avalo Therapeutics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Avalo Therapeutics (Avalo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avalo Therapeutics Inc (NAS:AVTX) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

C6K0:Germany C6K0:Germany

Address

540 Gaither Road, Suite 400, Rockville, MD, USA, 20850

Website

https://www.avalotx.com

Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006.

Executives

Armistice Capital Master Fund Ltd.	director, 10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Caissa Capital Management Ltd.	10 percent owner	PALM GROVE HOUSE, WICKHAMS CAY 1 ROAD TOWN, TORTOLA D8 VG1110
Christopher Ryan Sullivan	officer: Interim CFO	C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Garry Arthur Neil	officer: Chief Medical Officer	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Mitchell Chan	director	C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG MD 20878
Stephen Smolinski	officer: Chief Commercial Officer	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Magnus Persson	director	400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Joseph M Miller	director	C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Gilla Kaplan	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
June Sherie Almenoff	director	C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Schond L. Greenway	officer: CFO & Treasurer	C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850
H Jeffrey Wilkins	officer: Chief Medical Officer	600 LEE ROAD, SUITE 100, WAYNE PA 19087
Harrell James Archie Jr	officer: Chief Commercial Officer	C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Illya Keith Maher	director	C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	director, 10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022